Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Svennilson Peter (CIK 1606074) reported $1.23B across 7 reported positions in its SEC 13F filing for 2020-09-30. Largest positions: NGM ($286.7M, 23.39%), RVMD ($277.6M, 22.65%), NRIX ($235.8M, 19.24%), RAPT ($181.3M, 14.79%), CNST ($122.6M, 10.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | NGM | NGM Biopharmaceuticals Inc | $286.7M | 23.39% | 18.0M | Added |
| 2 | RVMD | Revolution Medicines Inc | $277.6M | 22.65% | 8.0M | Hold |
| 3 | NRIX | Nurix Therapeutics Inc | $235.8M | 19.24% | 6.8M | New |
| 4 | RAPT | RAPT Therapeutics Inc | $181.3M | 14.79% | 5.6M | Trimmed |
| 5 | CNST | Constellation Pharmceticls I | $122.6M | 10.00% | 6.1M | Hold |
| 6 | ORIC | ORIC Pharmaceuticals Inc. | $119.3M | 9.73% | 4.8M | Hold |
| 7 | GRTS | Gritstone Oncology Inc | $2.3M | 0.19% | 869,493 | Trimmed |
| 8 | RCUS | Arcus Biosciences Inc | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2020-09-30